Skip to content
TESCT — Trans European Stem Cell Therapy Society
Members of the society in discussion

The science

Stem cells,
without the hype.

What gene editing can actually do — and the questions the society believes must be answered before it is used in people.

Gene editing

Gene editing technologies

CRISPR-Cas9 was first described as a gene editing tool in 2012. In just a few years, the technology has exploded in popularity thanks to its promise of making genome editing much faster, cheaper and easier than ever before. CRISPR has changed the way scientists do research, but what everyone is expecting, either with excitement or fear, is its use in humans. In theory, CRISPR technology could let us edit any mutation at will and cure the disease it causes.

Potential applications of CRISPR are:

  • Cancer
  • Blood disorders
  • Blindness
  • AIDS
  • Cystic fibrosis
  • Muscular dystrophy
  • Huntington's disease

However, CRISPR-Cas9 is not without risks. Limitations can occur by variation of the genome-editing efficiency and/or “off-target effects”, where DNA is cut at sites other than the intended target. This can lead to the introduction of unintended mutations.

The high potential number of applications raises questions about the ethical merits and consequences of tampering with genomes.

“To better inform future public conversations recommended by the Napa meeting, research is needed to understand and manage risks arising from the use of the CRISPR-Cas9 technology. Considerations include the possibility of off-target alterations, as well as on-target events that have unintended consequences. It is critical to implement appropriate and standardized benchmarking methods to determine the frequency of off-target effects and to assess the physiology of cells and tissues that have undergone genome editing. At present, the potential safety and efficacy issues arising from the use of this technology must be thoroughly investigated and understood before any attempts at human engineering are sanctioned, if ever, for clinical testing. As with any therapeutic strategy, higher risks can be tolerated when the reward of success is high, but such risks also demand higher confidence in their likely efficacy. And, for countries whose regulatory agencies focus on safety and efficacy but not on broader social and ethical concerns, another venue is needed to facilitate public conversation.”

Given the speed with which the genome engineering field is evolving, the Napa meeting concluded that there is an urgent need for open discussion of the merits and risks of human genome modification by a broad cohort of scientists, clinicians, social scientists, the general public, and relevant public entities and interest groups.